3rdPartyFeeds

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GERN, WWE and CRON

NEW YORK, NY / ACCESSWIRE / March 20, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ... Read More...

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / March 20, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.” data-reactid=”12″>NEW YORK, NY / ACCESSWIRE / March 20, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Geron Corporation (GERN)
Class Period: March 19, 2018 to September 26, 2018
Lead Plaintiff Deadline: March 23, 2020″ data-reactid=”13″>Geron Corporation (GERN)
Class Period: March 19, 2018 to September 26, 2018
Lead Plaintiff Deadline: March 23, 2020

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Learn about your recoverable losses in GERN: http://www.kleinstocklaw.com/pslra-1/geron-corporation-et-al-loss-submission-form?id=5756&amp;from=1” data-reactid=”15″>Learn about your recoverable losses in GERN: http://www.kleinstocklaw.com/pslra-1/geron-corporation-et-al-loss-submission-form?id=5756&from=1

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="World Wrestling Entertainment, Inc. (WWE)
Class Period: February 7, 2019 to February 5, 2020
Lead Plaintiff Deadline: May 5, 2020″ data-reactid=”16″>World Wrestling Entertainment, Inc. (WWE)
Class Period: February 7, 2019 to February 5, 2020
Lead Plaintiff Deadline: May 5, 2020

The complaint alleges that during the class period World Wrestling Entertainment, Inc. made materially false and/or misleading statements and/or failed to disclose that: Defendants perpetrated a fraudulent scheme which: (i) deceived the investing public regarding WWE’s business and prospects; (ii) artificially inflated the price of WWE Class A common stock; (iii) permitted certain senior executives of WWE to sell more than $282 million worth of their personally held shares at fraud inflated prices; and (iv) caused the public to purchase WWE Class A common stock at artificially inflated prices.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Learn about your recoverable losses in WWE: http://www.kleinstocklaw.com/pslra-1/world-wrestling-entertainment-inc-loss-submission-form?id=5756&amp;from=1” data-reactid=”18″>Learn about your recoverable losses in WWE: http://www.kleinstocklaw.com/pslra-1/world-wrestling-entertainment-inc-loss-submission-form?id=5756&from=1

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Cronos Group Inc. (CRON)
Class Period: May 9, 2019 to March 2, 2020
Lead Plaintiff Deadline: May 11, 2020″ data-reactid=”19″>Cronos Group Inc. (CRON)
Class Period: May 9, 2019 to March 2, 2020
Lead Plaintiff Deadline: May 11, 2020

The complaint alleges that throughout the class period Cronos Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company’s ability to timely file its periodic reports; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Learn about your recoverable losses in CRON: http://www.kleinstocklaw.com/pslra-1/cronos-group-inc-loss-submission-form-2?id=5756&amp;from=1” data-reactid=”21″>Learn about your recoverable losses in CRON: http://www.kleinstocklaw.com/pslra-1/cronos-group-inc-loss-submission-form-2?id=5756&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com” data-reactid=”24″>CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SOURCE: The Klein Law Firm” data-reactid=”25″>SOURCE: The Klein Law Firm

View source version on accesswire.com:
https://www.accesswire.com/581786/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-GERN-WWE-and-CRON

Read More

Add Comment

Click here to post a comment